Tebentafusp (tebe) in a real-world cohort of 72 French metastatic uveal melanoma (UM) patients (pts).
Sophie Piperno‐Neumann(Institut Curie), Manuel Rodrigues(Inserm), Vincent Servois(Institut Curie), Marc Pracht(Canadian Partnership Against Cancer), N. Litrowski(Groupe Hospitalier du Havre), Léah Mailly-Giacchetti(Inserm), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Pierre Combe(Hôpital Européen Georges-Pompidou), Jean Christophe Théry(Centre Henri Becquerel), Mathilde Saint‐Ghislain(Inserm), Leanne de Koning(Institut Curie), Toulsie Ramtohul(Université Paris Sciences et Lettres), Hélène Martin(Centre Hospitalier Régional de Metz-Thionville), Agathe Garcia(Institut Curie)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k